These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1804562)

  • 1. Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic.
    Mimoto T; Imai J; Tanaka S; Hattori N; Takahashi O; Kisanuki S; Nagano Y; Shintani M; Hayashi H; Sakikawa H
    Chem Pharm Bull (Tokyo); 1991 Sep; 39(9):2465-7. PubMed ID: 1804562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere.
    Kiso Y
    Biopolymers; 1996; 40(2):235-44. PubMed ID: 8785365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic.
    Kiso Y; Matsumoto H; Mizumoto S; Kimura T; Fujiwara Y; Akaji K
    Biopolymers; 1999; 51(1):59-68. PubMed ID: 10380353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic.
    Mimoto T; Imai J; Tanaka S; Hattori N; Kisanuki S; Akaji K; Kiso Y
    Chem Pharm Bull (Tokyo); 1991 Nov; 39(11):3088-90. PubMed ID: 1799953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KMI-008, a novel beta-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides.
    Shuto D; Kasai S; Kimura T; Liu P; Hidaka K; Hamada T; Shibakawa S; Hayashi Y; Hattori C; Szabo B; Ishiura S; Kiso Y
    Bioorg Med Chem Lett; 2003 Dec; 13(24):4273-6. PubMed ID: 14643307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substrate analog inhibitors of HIV-1 protease containing phenylnorstatine as a transition state element.
    Raju B; Deshpande MS
    Biochem Biophys Res Commun; 1991 Oct; 180(1):181-6. PubMed ID: 1930214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
    Mimoto T; Kato R; Takaku H; Nojima S; Terashima K; Misawa S; Fukazawa T; Ueno T; Sato H; Shintani M; Kiso Y; Hayashi H
    J Med Chem; 1999 May; 42(10):1789-802. PubMed ID: 10346931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.
    Le VD; Mak CC; Lin YC; Elder JH; Wong CH
    Bioorg Med Chem; 2001 May; 9(5):1185-95. PubMed ID: 11377177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine.
    Kimura T; Shuto D; Kasai S; Liu P; Hidaka K; Hamada T; Hayashi Y; Hattori C; Asai M; Kitazume S; Saido TC; Ishiura S; Kiso Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1527-31. PubMed ID: 15006396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure.
    Mimoto T; Terashima K; Nojima S; Takaku H; Nakayama M; Shintani M; Yamaoka T; Hayashi H
    Bioorg Med Chem; 2004 Jan; 12(1):281-93. PubMed ID: 14697794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere.
    Mimoto T; Hattori N; Takaku H; Kisanuki S; Fukazawa T; Terashima K; Kato R; Nojima S; Misawa S; Ueno T; Imai J; Enomoto H; Tanaka S; Sakikawa H; Shintani M; Hayashi H; Kiso Y
    Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1310-26. PubMed ID: 10993230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
    Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
    Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
    Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
    Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.
    Baldwin ET; Bhat TN; Gulnik S; Liu B; Topol IA; Kiso Y; Mimoto T; Mitsuya H; Erickson JW
    Structure; 1995 Jun; 3(6):581-90. PubMed ID: 8590019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel dipeptide-based HIV protease inhibitor containing allophenylnorstatine.
    Abdel-Rahman HM; el-Koussi NA; Alkaramany GS; Youssef AF; Kiso Y
    Arch Pharm (Weinheim); 2004 Nov; 337(11):587-98. PubMed ID: 15540219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic.
    Maegawa H; Kimura T; Arii Y; Matsui Y; Kasai S; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5925-9. PubMed ID: 15501070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
    Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y
    J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine.
    Mimoto T; Imai J; Kisanuki S; Enomoto H; Hattori N; Akaji K; Kiso Y
    Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2251-3. PubMed ID: 1423795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin.
    Hidaka K; Kimura T; Ruben AJ; Uemura T; Kamiya M; Kiso A; Okamoto T; Tsuchiya Y; Hayashi Y; Freire E; Kiso Y
    Bioorg Med Chem; 2008 Dec; 16(23):10049-60. PubMed ID: 18952439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of pseudo-symmetric HIV protease inhibitors containing a novel hydroxymethylcarbonyl (HMC)-hydrazide isostere.
    Hidaka K; Kimura T; Hayashi Y; McDaniel KF; Dekhtyar T; Colletti L; Kiso Y
    Bioorg Med Chem Lett; 2003 Jan; 13(1):93-6. PubMed ID: 12467624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.